Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BIOTEMPT B.V. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is being reviewed by 1 distinct examiner, CATHERINE S HIBBERT. The matter is situated within 1 distinct art unit, reflecting a singular administrative and technical classification for the company's current filing.
CATHERINE S HIBBERT is the busiest examiner for this entity, currently managing 1 pending office action. Since there is only 1 distinct examiner and 1 distinct art unit, the prosecution of this biotechnological technology is highly centralized. The outcome of the 1 pending office action depends entirely on the interactions between the applicant and this single examiner within the designated art unit.
Practitioners should note that the lack of multiple pending actions prevents any comparison of examiner behavior or art unit standards within this portfolio. The prosecution strategy is focused on the 1 pending office action handled by CATHERINE S HIBBERT. This concentration means that the company's current presence in the biotechnology patent landscape is defined by this single active matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBBERT, CATHERINE S | 1 | 58.8% | +48.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029174 | AUTOPHAGY-INHIBITING PEPTIDE AND ORGANIC ACID SALT THEREOF ADDRESSING ISSUES OF VASCULAR PERMEABILITY | HIBBERT, CATHERINE S | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18029174 | AUTOPHAGY-INHIBITING PEPTIDE AND ORGANIC ACID SALT THEREOF ADDRESSING ISSUES OF VASCULAR PERMEABILITY | HIBBERT, CATHERINE S | 1658 | §102DP | Final Rejection | — | Pending | Mar 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOTEMPT B.V. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Catherine S Hibbert has the most, with 1 of BIOTEMPT B.V.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
